ViroPharma Inc. Hits New 52-Week High at $41.00 (VPHM)
Shares of ViroPharma (NASDAQ:VPHM) hit a new 52-week high on Friday, Analyst Ratings Network reports. The company traded as high as $41.00 and last traded at $40.71, with a volume of 738,853 shares trading hands. The stock had previously closed at $39.80.
A number of research firms have recently commented on VPHM. Analysts at Ned Davis Research downgraded shares of ViroPharma (NASDAQ:VPHM) from a “neutral” rating to a “sell” rating in a research note to investors on Monday. Separately, analysts at Deutsche Bank downgraded shares of ViroPharma (NASDAQ:VPHM) from a “buy” rating to a “hold” rating in a research note to investors on Thursday, September 19th. They now have a $43.00 price target on the stock, up previously from $38.00. Finally, analysts at Merrill Lynch downgraded shares of ViroPharma (NASDAQ:VPHM) from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, September 18th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $37.63.
ViroPharma has a 52 week low of $22.12 and a 52 week high of $40.89. The stock has a 50-day moving average of $34.33 and a 200-day moving average of $29.42. The company’s market cap is $2.673 billion.
ViroPharma (NASDAQ:VPHM) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.14. The company had revenue of $104.00 million for the quarter, compared to the consensus estimate of $105.06 million. During the same quarter in the previous year, the company posted ($0.06) earnings per share. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. On average, analysts predict that ViroPharma will post $-0.78 earnings per share for the current fiscal year.
ViroPharma Incorporated (NASDAQ:VPHM) is an international biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.